Abstract
Introduction: Little information is available on the pattern of use of antipsychotics in naturalistic
conditions in persons initially treated with “conventional” mood stabilizers (lithium
and anticonvulsants).
Methods: Data on community prescriptions were extracted from the 2004–2006 claims database
of a French health care insurance fund for self-employed workers. Patients included
were those continuously exposed to mood stabilizers without concomitant dispensing
of antipsychotics over at least a 3-month period.
Results: Of the 3 958 persons included, 17.8% had at least one addition/switch to antipsychotics
over the follow-up period. The most frequent pattern was addition of second-generation
antipsychotics (SGAPs) (41%) or first-generation antipsychotics (FGAPs) (23%) to the
mood stabilizer for a relatively short period of time. A switch from mood stabilizer
to SGAPs (20%) or FGAPs (15%) was less frequent. Mood stabilizers alone were prescribed
again in most patients with the addition of FGAPs (72%) or SGAPs (61%) to mood stabilizers.
Conversely, the majority of patients with a switch from mood stabilizers to FGAPs
(55%) or SGAPs (58%) went on with these latter treatments over the follow-up.
Conclusions: SGAPs are preferentially prescribed in combination with mood stabilizers and their
pattern of use is similar to that of FGAPs.
References
- 1
Aparasu RR, Bhatara V, Gupta S.
U. S. national trends in the use of antipsychotics during office visits, 1998–2002.
Ann Clin Psychiatry.
2005;
17
147-152
- 2
Ashcroft DM, Frischer M, Lockett J. et al .
Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional
study.
Pharmacoepidemiol Drug Saf.
2002;
11
285-289
- 3
Baldessarini RJ, Leahy L, Arcona S. et al .
Patterns of psychotropic drug prescription for U. S. patients with diagnoses of bipolar
disorders.
Psychiatr Serv.
2007;
58
85-91
- 4
Bauer MS, Mitchner L.
What is a “mood stabilizer”? An evidence-based response.
Am J Psychiatry.
2004;
161
3-18
- 5
Bellantuono C, Barraco A, Rossi A. et al .
The management of bipolar mania: a national survey of baseline data from the EMBLEM
study in Italy.
BMC Psychiatry.
2007;
7
33
- 6
Berghofer A, Alda M, Adli M. et al .
Long-term effectiveness of lithium in bipolar disorder: A multicenter investigation
of patients with typical and atypical features.
J Clin Psychiatry.
2008;
69
1860-1868
- 7
Caceres MC, Penas-Lledo EM, de la Rubia A. et al .
Increased use of second generation antipsychotic drugs in primary care: potential
relevance for hospitalizations in schizophrenia patients.
Eur J Clin Pharmacol.
2008;
64
73-76
- 8 Crismon ML, Argo T, SD B. et al .
Texas Medication Algorithm Project. Bipolar Disorder Algorithms Procedural Manual. Texas Department of State Health Services 2007
- 9
Essock SM, Covell NH, Davis SM. et al .
Effectiveness of switching antipsychotic medications.
Am J Psychiatry.
2006;
163
2090-2095
- 10
Garver D, Lazarus A, Rajagopalan K. et al .
Racial differences in medication switching and concomitant prescriptions in the treatment
of bipolar disorder.
Psychiatr Serv.
2006;
57
666-672
- 11
Ghaemi SN, Hsu DJ, Thase ME. et al .
Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants.
Psychiatr Serv.
2006;
57
660-655
- 12
Kaye JA, Bradbury BD, Jick H.
Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom
from 1991 to 2000: a population-based observational study.
Br J Clin Pharmacol.
2003;
56
569-575
- 13
Li J, McCombs JS, Stimmel GL.
Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program.
J Affect Disord.
2002;
71
131-139
- 14
Maj M.
The impact of lithium prophylaxis on the course of bipolar disorder: A review of the
research evidence.
Bipolar Disord.
2000;
2
93-101
- 15
NICE: Bipolar disorder
.
The management of bipolar disorder in adults, children and adolescents, in primary
and secondary care in Clinical Guideline No 38. National Institute for Health and Clinical Excellence 2006
- 16
Russo P, Smith MW, Dirani R. et al .
Pharmacotherapy patterns in the treatment of bipolar disorder.
Bipolar Disord.
2002;
4
366-377
- 17
Sankaranarayanan J, Puumala SE.
Antipsychotic use at adult ambulatory care visits by patients with mental health disorders
in the United States, 1996–2003: national estimates and associated factors.
Clin Ther.
2007;
29
723-741
- 18
Sernyak MJ, Griffin RA, Johnson RM. et al .
Neuroleptic exposure following inpatient treatment of acute mania with lithium and
neuroleptic.
Am J Psychiatry.
1994;
151
133-135
- 19
Stata Statistical Software
.
Release 9.0. College Station. Texas, Stata Corporation 2005
- 20
Taylor M, Shajahan P, Lawrie SM.
Comparing the use and discontinuation of antipsychotics in clinical practice: an observational
study.
J Clin Psychiatry.
2008;
69
240-245
- 21
Tondo L, Baldessarini RJ, Floris G.
Long-term clinical effectiveness of lithium maintenance treatment in types I and II
bipolar disorders.
Br J Psychiatry Suppl.
2001;
41
S184-S190
- 22
Tschoner A, Engl J, Rettenbacher M. et al .
Effects of six second generation antipsychotics on body weight and metabolism − risk
assessment and results from a prospective study.
Pharmacopsychiatry.
2009;
42
29-34
- 23
Verdoux H, Gonzales B, Takei N. et al .
A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive
outpatients.
J Affect Disord.
1996;
38
81-87
- 24
Verdoux H, Tournier M.
Trends in costs of antipsychotics in France.
Eur Psychiatry.
2009;
24
214-215
- 25
Weinbrenner S, Assion HJ, Stargardt T. et al .
Drug prescription patterns in schizophrenia outpatients: analysis of data from a German
health insurance fund.
Pharmacopsychiatry.
2009;
42
66-71
- 26
Weissman EM.
Antipsychotic prescribing practices in the Veterans Healthcare Administration − New
York metropolitan region.
Schizophr Bull.
2002;
28
31-42
- 27
Yatham LN, Kennedy SH, O’Donovan C. et al .
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management
of patients with bipolar disorder: update 2007.
Bipolar Disord.
2006;
8
721-739
Correspondence
Prof. H. Verdoux
Hôpital Charles Perrens
121 rue de la Béchade
33076 Bordeaux Cedex
France
Telefon: +33/556/56 17 32
Fax: +33/556/56 35 46
eMail: helene.verdoux@u-bordeaux2.fr